Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

That means it aspires to directly compete with the likes of Eli Lilly and Novo Nordisk, the big pharmas that currently split the bulk of the market for weight loss drugs. Per new data it presented at ...